Metastatic Colorectal Cancer: Decoding Complex Treatment Algorithms Through Debates and Cases

Provided by The University of Nebraska Medical Center, Center for Continuing Education.

This activity is supported by an independent education grant from Genentech Inc., Taiho Oncology Inc., and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Scroll to the Bottom of this Information to Begin this Course

Release date: January 23, 2017

Valid through: January 23, 2018

Specialty: Oncology

Media: Internet

Estimated Time to Complete Activity: 60 minutes

Target Audience

This activity is intended for:

  1. medical oncologists
  2. HCPs
  3. physicians-in-training
  4. oncology nurses
  5. nurse practitioners
  6. pharmacists
  7. physician assistants

Program Overview

Metastatic colorectal cancer (CRC) is the third most common malignancy in both men and women and the second leading cause of cancer mortality in the United States. Overall survival rates for patients with advanced CRC at 1 and 2 years have increased dramatically due to the development of new cytotoxic and targeted treatments in the past two decades. The proliferation of new treatments for advanced CRC have improved patient outcomes, but present clinicians with new challenges in selecting appropriate therapies based on patient- and disease-specific factors, including molecular testing and toxicities, as well as designing treatment plans based on the concept of continuum of care. Clinicians specializing in CRC will benefit from a debate session in this first part of a two-session series. Faculty will review the latest safety and efficacy data of available treatments, as well as, debate on the benefits and challenges faced in the first, second, and beyond lines for metastatic CRC. The aim of the program is to provide education on integrating effective treatment plans to personalize treatment for patients with metastatic CRC.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Examine the latest safety and efficacy data of available treatments in the first, second, and beyond lines for metastatic CRC
  • Compare the benefits and challenges among available CRC treatments in first-, second-, and third-line settings
  • Summarize the key results from the abstracts presented at the 2017 Gastrointestinal Cancers Symposium (ASCO GI)
  • Evaluate and select optimal treatment algorithms for patients with metastatic CRC
  • Appraise the emerging application of immunotherapy for metastatic CRC

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Wen Wee Ma, MD

Wen Wee Ma, MD

Senior Associate Consultant, Medical Oncology
Mayo Clinic

Joleen M. Hubbard, MD

Joleen M. Hubbard, MD

Assistant Professor of Oncology
Mayo Clinic

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education.

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Live Activity
The University of Nebraska Medical Center, Center for Continuing Education designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of credit for completing this program.

Disclosures of Conflicts of Interest

Presenters

Joleen Hubbard, MD
  • Research support (to Mayo Clinic): Boston Biomedical, Inc.; Merck; Genentech; Senhwa Biosciences, Inc.
  • Advisory board: (honorarium to Mayo Clinic): Boehringer Ingelheim; Genentech
Wen Wee Ma, MBBS
  • Research support (to Mayo Clinic): Bayer

University of Nebraska Medical Center, Center for Continuing Education

Lois Colburn, Executive Director
  • Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator
  • Has nothing to disclose.

University of Nebraska Medical Center, Peer Reviewer

Lyudmyla Berim, MD
  • Has nothing to disclose.

PlatformQ Health Education, LLC

Hamsa Jaganathan, PhD, Medical Director
  • Has nothing to disclose.
Karen Greb-Murphy, Program Manager
  • Has nothing to disclose.

Instructions for Participation and Credit

There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

Hardware and Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclosure of Unlabeled Use

The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

Disclaimer

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.